IOVA IOVANCE BIOTHERAPEUTICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1425205 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY51.3%
TTM net income YoY44.5%
TTM EPS YoY58.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin53.2%
Operating margin-60.8%
Net margin-58.2%
FCF margin-57.0%
EBITDA margin-54.0%
Returns
ROE-29.1%
ROA-23.3%
ROIC (approx.)-28.0%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $263.50M | $164.07M |
| Cost of revenue | $173.18M | $93.25M |
| Gross profit | $90.32M | $70.82M |
| R&D expense | $300.27M | $276.23M |
| SG&A expense | $152.32M | $152.27M |
| Operating income | -$403.36M | -$395.28M |
| Pretax income | -$393.05M | -$375.00M |
| Income tax | -$2.07M | -$2.83M |
| Net income | -$390.98M | -$372.18M |
| EBITDA | -$390.49M | -$384.02M |
| EPS (basic) | -1.09 | -1.28 |
| EPS (diluted) | -1.09 | -1.28 |
| Weighted avg. shares (diluted) | 357,345 | 289,877 |
| Balance sheet | ||
| Cash & equivalents | $163.08M | $122.05M |
| Short-term investments | $133.90M | $208.09M |
| Receivables | $82.45M | $69.34M |
| Inventory | $51.68M | $51.52M |
| Current assets | $442.69M | $457.02M |
| PP&E, net | $131.11M | $109.08M |
| Intangibles | $279.32M | $282.40M |
| Total assets | $913.17M | $910.43M |
| Current liabilities | $138.36M | $122.34M |
| Total liabilities | $214.59M | $200.02M |
| Shareholders' equity | $698.58M | $710.40M |
| Shares outstanding | 411.94M | 305.25M |
| Cash flow statement | ||
| Operating cash flow | -$302.41M | -$352.98M |
| Capital expenditure | $33.84M | $11.07M |
| Free cash flow | -$336.24M | -$364.05M |
| Investing cash flow | $47.50M | -$96.41M |
| Financing cash flow | $300.77M | $390.66M |
| Depreciation & amortization | $12.86M | $11.26M |
| Stock-based compensation | $61.58M | $109.63M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.